{"product_id":"cardinalhealth-bcg-matrix","title":"Cardinal Health Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCardinal Health’s preliminary BCG Matrix highlights a mixed portfolio—high-growth segments show Star potential in specialty distribution, while mature medical-supply lines function as Cash Cows funding innovation; some legacy businesses behave like Dogs and merit divestment consideration. This snapshot points to strategic trade-offs between margin preservation and reinvestment to capture emerging healthcare channels. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and downloadable Word and Excel files to guide capital allocation and product strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmaceutical Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty Pharmaceutical Distribution sits as a Star: global specialty drug spend reached about $420B in 2025 with oncology and immunology growing ~12–15% YoY, and Cardinal Health holds a top-three distribution share, using scale to handle biologics\/biosimilars and earn higher gross margins than generics. \u003c\/p\u003e\n\u003cp\u003eTo keep leadership, Cardinal must keep investing in cold-chain networks and analytics—capex for specialty logistics rose industry-wide to ~$3–4B in 2024–25—and this segment is on track to become a major cash generator as market growth moderates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNuclear and Precision Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a leader in radiopharmaceuticals, Cardinal Health’s Nuclear and Precision Health unit sits in the BCG Matrix Stars quadrant, driven by a radiopharma market growing ~12% CAGR to reach $12.5B by 2028 (IQVIA 2025) and rising PET\/theranostics demand.\u003c\/p\u003e\n\u003cp\u003eCardinal’s ~100 nuclear pharmacies and nationwide distribution give first-to-market reach that rivals struggle to copy, supporting \u0026gt;$1.2B segment revenue in 2024 (Cardinal 2024 10-K).\u003c\/p\u003e\n\u003cp\u003eMaintaining growth needs high capex—estimated $150–250M annually for cold-chain, compliance, and license expansion—to support new drug approvals and CMS\/regulatory rules.\u003c\/p\u003e\n\u003cp\u003eThe unit is a critical growth engine aligning with personalized medicine trends, improving margins and market share as precision diagnostics and targeted therapies expand. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAt-Home Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCardinal Healths At-Home business is a star: home-based care grew ~9% CAGR 2020–2025 and the US home health market hit $173B in 2025, positioning Cardinal to capture large share by supplying chronic patients directly.\u003c\/p\u003e\n\u003cp\u003eDemographic tailwinds—US 65+ population rose 15% from 2015–2025—drive demand; Cardinal’s brand and clinical distribution networks give it a strong advantage in this fast-growing segment.\u003c\/p\u003e\n\u003cp\u003eTo scale, Cardinal invested heavily in e-commerce and last-mile logistics, allocating $300M+ in 2024–2025 to digital platforms and fulfillment, matching growth needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptiFreight Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOptiFreight Logistics is a Star in Cardinal Health’s BCG matrix, driving double-digit growth by cutting clients’ freight costs up to 12% and improving fill rates amid 2023–2025 shipping volatility.\u003c\/p\u003e\n\u003cp\u003eCardinal holds a leading share in specialized healthcare logistics (estimated ~30% U.S. market for medical-supply freight management in 2024), delivering high value via real-time, data-driven route and spend analytics.\u003c\/p\u003e\n\u003cp\u003eHigh tech spend—annual R\u0026amp;D\/IT updates consuming an estimated $40–60M—keeps competitiveness; the unit is capital-hungry but yields strong margin expansion when scale is maintained.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives ~12% client freight savings\u003c\/li\u003e\n\u003cli\u003e~30% U.S. niche market share (2024)\u003c\/li\u003e\n\u003cli\u003e$40–60M annual tech\/IT spend\u003c\/li\u003e\n\u003cli\u003eHigh growth, high investment, strong margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Pharma Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardinal Healths Bio-Pharma Services is a Star: clinical-trial support and real-world evidence (RWE) grew ~18% in 2024 as the unit won multimillion-dollar contracts, giving Cardinal a top-3 share in several emerging service lines for mid-size pharma. \u003c\/p\u003e\n\u003cp\u003eThe segment captures value across the drug lifecycle, leveraging regulatory expertise amid rising trial complexity; sustained hires and $120M+ data-integration spend planned for 2025 are critical to retain growth and market share. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue growth ~18%\u003c\/li\u003e\n\u003cli\u003eTop-3 market share in select mid-size pharma services\u003c\/li\u003e\n\u003cli\u003e$120M+ planned 2025 data\/IT spend\u003c\/li\u003e\n\u003cli\u003eFocus: clinical trials, RWE, regulatory consulting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑growth healthcare portfolio: $3.5B+ revenue, heavy $700–900M capex to scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Specialty pharma, Nuclear \u0026amp; Precision Health, At‑Home, OptiFreight, and Bio‑Pharma Services drive high growth and require heavy capex\/tech spend to retain share; combined 2024 revenue ~ $3.5B+, capex\/IT run-rate ~$700–900M (2024–25), sector CAGRs 9–18% (2024–28), Nuclear revenue \u0026gt;$1.2B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCapex\/IT\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Pharma\u003c\/td\u003e\n\u003ctd\u003e$1.0B+\u003c\/td\u003e\n\u003ctd\u003e12–15% YoY\u003c\/td\u003e\n\u003ctd\u003e$150–250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNuclear\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003ctd\u003e~12% CAGR\u003c\/td\u003e\n\u003ctd\u003eIncluded above\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAt‑Home\u003c\/td\u003e\n\u003ctd\u003e$600M+\u003c\/td\u003e\n\u003ctd\u003e~9% CAGR\u003c\/td\u003e\n\u003ctd\u003e$300M (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOptiFreight\u003c\/td\u003e\n\u003ctd\u003e$200M+\u003c\/td\u003e\n\u003ctd\u003eDouble‑digit\u003c\/td\u003e\n\u003ctd\u003e$40–60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio‑Pharma Services\u003c\/td\u003e\n\u003ctd\u003e$500M+\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003ctd\u003e$120M planned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG review of Cardinal Health’s units with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix mapping Cardinal Health units into quadrants for fast strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Pharmaceutical Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU.S. Pharmaceutical Distribution is Cardinal Health’s cash cow, holding roughly 20–25% share of U.S. drug distribution and moving over $150 billion in pharmaceuticals annually (Cardinal FY2024 revenue mix). The segment operates in a low-growth, highly mature market yet delivers high-volume cash flow—about $2–3 billion in operating cash flow yearly—that services debt, funds dividends, and backs star investments. Efficiency comes from \u0026gt;90% automated DCs and multidecade contracts with major pharmacy chains, keeping margins stable around mid-single digits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical-Surgical Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardinal Health is a leading North American distributor of surgical kits, gloves, and basic medical supplies, capturing roughly 20%–25% share in hospital supply distribution as of 2025 and generating steady gross margins near 12% in this segment.\u003c\/p\u003e\n\u003cp\u003eMarket growth for core medical-surgical products is low, ~2% CAGR; Cardinal’s scale drives high operating leverage, producing reliable cash flow—medical-surgical contributed about $3.1 billion of operating cash flow in FY 2024.\u003c\/p\u003e\n\u003cp\u003eCapital allocation here targets process automation and procurement optimization rather than share-grabbing; annual reinvestment equals low-single-digit percent of segment revenue, preserving liquidity.\u003c\/p\u003e\n\u003cp\u003eThis cash cow funds Cardinal’s push into higher-margin specialty services and solutions, supporting strategic deals and R\u0026amp;D without stressing the balance sheet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRed Oak Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRed Oak Sourcing, Cardinal Health’s joint venture for generic procurement, sustains high market share in affordable-drug sourcing—handling roughly $4.2 billion in annualized purchasing volume in 2024 and securing low single-digit procurement margins above peers. \u003c\/p\u003e\n\u003cp\u003eBy aggregating volume, Cardinal cuts COGS by an estimated 120–180 basis points versus standalone buys, keeping gross margins steady in a low-growth generic market (~1–2% annual unit growth). \u003c\/p\u003e\n\u003cp\u003eCash from sourcing efficiencies funded about $350 million of free cash flow in FY2024, consistently strengthening Cardinal’s balance sheet and funding dividends and buybacks. \u003c\/p\u003e\n\u003cp\u003eWith minimal marketing spend and entrenched supplier contracts, Red Oak remains a textbook cash cow requiring little promotional investment to sustain returns. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRetail Pharmacy Solutions: through Medicine Shoppe and Medicap Pharmacy franchises, Cardinal Health supports ~5,500 independent pharmacies (2024 company data) with POS, inventory, compliance, and marketing tools; market is mature so focus is retention and steady service-fee income.\u003c\/p\u003e\n\u003cp\u003eHigh share among independents yields stable, low-capex cash flow—estimated mid-to-high single-digit EBITDA margin—and profits are redirected to digital health and specialty pharmacy growth initiatives (Cardinal invested $300m+ in related programs in 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports ~5,500 independent pharmacies (2024)\u003c\/li\u003e\n\u003cli\u003ePrimary goal: retention, steady service fees\u003c\/li\u003e\n\u003cli\u003eLow capex, stable mid-to-high single-digit EBITDA margins\u003c\/li\u003e\n\u003cli\u003e2024 cash redeployed: $300m+ to digital health and specialty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLaboratory Products is a high-share, steady cash cow for Cardinal Health: diagnostic equipment and consumables supply hospitals and private labs, with demand tracking healthcare utilization not volatile trends; FY2025 lab distribution likely contributed low-single-digit organic growth and stable gross margins around historical mid-20s percent.\u003c\/p\u003e\n\u003cp\u003eCardinal’s deep hospital supply-chain integration creates high switching costs, keeping new entrants out, so the segment generates reliable free cash flow and needs modest maintenance capex to sustain productivity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady demand tied to hospital utilization\u003c\/li\u003e\n\u003cli\u003eHigh market share, mid-20s% gross margin\u003c\/li\u003e\n\u003cli\u003eLow capex, reliable free cash flow\u003c\/li\u003e\n\u003cli\u003eStrong supply-chain lock-in vs entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardinal Health’s cash cows: $5–6B FCF fuels specialty growth \u0026amp; dividends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCardinal Health’s cash cows—U.S. pharma distribution, medical-surgical, Red Oak sourcing, retail pharmacy services, and lab products—deliver steady free cash flow (~$5–6B combined FY2024–25), mid-single-digit to mid-teens margins, and low reinvestment (low-single-digit % revenue), funding specialty growth and dividends.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eFY24–25 cash\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma distribution\u003c\/td\u003e\n\u003ctd\u003e$2–3B\u003c\/td\u003e\n\u003ctd\u003emid SD pts\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed-surgical\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003ctd\u003e~12% gross\u003c\/td\u003e\n\u003ctd\u003e~2% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRed Oak\u003c\/td\u003e\n\u003ctd\u003e$350M FCF\u003c\/td\u003e\n\u003ctd\u003elow SD pts\u003c\/td\u003e\n\u003ctd\u003e1–2% units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail services\u003c\/td\u003e\n\u003ctd\u003estable fees\u003c\/td\u003e\n\u003ctd\u003emid–high SD EBITDA\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab products\u003c\/td\u003e\n\u003ctd\u003ereliable FCF\u003c\/td\u003e\n\u003ctd\u003emid-20s% gross\u003c\/td\u003e\n\u003ctd\u003e~1–2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eCardinal Health BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Cardinal Health BCG Matrix you'll receive after purchase—no watermarks, no demo content, just a fully formatted, strategy-ready matrix tailored for portfolio analysis and decision-making.\u003c\/p\u003e\n\u003cp\u003eThis preview is identical to the downloadable report delivered upon purchase, crafted with market-backed insights and formatted for immediate use in presentations, planning, or further editing.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual document that becomes yours with a one-time purchase—professionally designed and analysis-ready for team briefings or client deliverables.\u003c\/p\u003e\n\u003cp\u003eThe report here matches exactly what will be emailed to you: clear, concise, and formatted by strategy experts to plug directly into your business planning or investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748037636473,"sku":"cardinalhealth-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cardinalhealth-bcg-matrix.png?v=1772204096","url":"https:\/\/matrixbcg.com\/products\/cardinalhealth-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}